Binodenoson
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2004 (NCT00944294)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A2a receptorAGONIST
ADORA2A agonist
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(N/N=C/C2CCCCC2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O- Mol. weight
- 391.43 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1950554 ↗
Also known as
- 2-((cyclohexylmethylene)hydrazino)adenosine
- 2-((cyclohexylmethylene)hydrazino)adenosine
- 2-(cyclohexylmethylidenehydrazino)adenosine
- binodenoson
- binodenoson
- binodenoson
- binodenoson
- binodenoson
- mre0470
- mre0470
- mre 0470
- mre 0470
- wrc 0470
- wrc-0470
- wrc-0470
- wrc-0470
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00944970 | Phase 3 | Oct 1, 2005 | Pfizer |
| NCT00944294 | Phase 3 | Feb 1, 2004 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2004 |
1 organizations
Page 1 / 1